Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wanted: Young Fogartys

This article was originally published in Start Up

Executive Summary

The Stanford University Medical Center has long been a hotbed of medical device innovation. In combination with the fertile atmosphere for innovation and technology development that exists there, the San Francisco Bay area has become the premier region in the US for new device creation. In an effort to capture, preserve and pass on this inventive and entrepreneurial spirit, Stanford is launching a Biomedical Technology Innovation program designed to cover in a year-long series of courses the essential skills for the development of new biomedical technologies. The program is primarily looking to draw people from medicine and engineering, although they will also consider candidates with relevant business experience. The program will bring experienced device start-up entrepreneurs, as well as experts in all of the ancillary fields necessary for a successful start-up, including patent attorneys, regulatory and reimbursement experts, and manufacturing and clinical testing executives. A small pilot program will begin in September 2001.

You may also be interested in...



Duke Takes Device Exec Ed on the Road

Duke University's Fuqua School of Business has taken the next step in making executive education easier and more convenient for busy managers. In the same way that executive MBA programs have now been designed to be completed on weekends, minimizing the intrusion into the work week, Duke has organized a medical device executive education program that is conducted on-site at device companies.

Embolic Protection: Better Outcomes Not Enough

For 20 years, interventional cardiologists denied the need for embolic protection devices, considering embolic events to generally be the infrequent results of poor technique. Nevertheless, recent data has revealed embolization as a potentially serious and relatively common event during percutaneous coronary interventions. While embolic protection devices have been shown to dramatically reduce embolic complications, physician adoption is slow. Several companies are developing different approaches to protect against embolization, recognizing that better patient data alone isn't enough to convince interventionalists to employ these devices.

Embolic Protection: Better Outcomes Not Enough

For 20 years, interventional cardiologists denied the need for embolic protection devices, considering embolic events to generally be the infrequent results of poor technique. Nevertheless, recent data has revealed embolization as a potentially serious and relatively common event during percutaneous coronary interventions. While embolic protection devices have been shown to dramatically reduce embolic complications, physician adoption is slow. Several companies are developing different approaches to protect against embolization, recognizing that better patient data alone isn't enough to convince interventionalists to employ these devices.

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel